TNF and uveitis: Methotrexate and more recently anti-tumor necrosis factor alpha (TNFα) have allowed a marked improvement in the functional prognosis of severe inflammatory pediatric uveitis, as demonstrated in the ADJUVITE and SYCAMORE trials (12, 13).